Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Prager, GW; Lackner, EM; Krauth, MT; Unseld, M; Poettler, M; Laffer, S; Cerny-Reiterer, S; Lamm, W; Kornek, GV; Binder, BR; Zielinski, CC; Valent, P.
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.
Mol Oncol. 2010; 4(2): 150-160.
Doi: 10.1016/j.molonc.2010.01.002
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Lackner Eva-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Cancer progression is often associated with the formation of malignant effusions. Vascular endothelial growth factor (VEGF) is a major regulator of vascular permeability and has been implicated as mediator of tumor progression. We examined the production and secretion of VEGF(165) in various primary cancer cells derived from malignant effusions, and the role of exogenous VEGF(165) as a mediator of effusion formation. VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin. Secreted VEGF(165) showed functional activity by inducing endothelial leakiness and tumor cell-transendothelial migration in vitro, effects which could be reverted by the anti-VEGF antibody bevacizumab. Thus, mTOR inhibitors as well as bevacizumab should be considered as potential agents in cancer patients suffering from malignant effusions.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiogenesis Inhibitors - pharmacology
- Antibiotics, Antineoplastic - administration and dosage
- Antibodies, Monoclonal - pharmacology
- Antibodies, Monoclonal, Humanized -
- Apoptosis - drug effects
- Cell Culture Techniques -
- Cell Line, Tumor -
- Cell Movement - drug effects
- Endothelium - pathology
- Gene Expression Regulation, Neoplastic - drug effects
- Humans -
- Intracellular Signaling Peptides and Proteins - antagonists and inhibitors
- Neoplasms - drug therapy
- Protein-Serine-Threonine Kinases - antagonists and inhibitors
- Recombinant Proteins - metabolism
- Sirolimus - administration and dosage
- TOR Serine-Threonine Kinases -
- Vascular Endothelial Growth Factor A - antagonists and inhibitors
- Find related publications in this database (Keywords)
- Cancer
- VEGF
- mTOR protein
- Rapamycin
- Bevacizumab